News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
712,246 Results
Type
Article (43542)
Company Profile (270)
Press Release (668434)
Multimedia
Podcasts (57)
Webinars (14)
Section
Business (205724)
Career Advice (2037)
Deals (35602)
Drug Delivery (97)
Drug Development (82246)
Employer Resources (172)
FDA (16366)
Job Trends (14979)
News (348166)
Policy (32805)
Tag
Academia (2666)
Accelerated approval (8)
Adcomms (24)
Allergies (98)
Alliances (50315)
ALS (109)
Alzheimer's disease (1463)
Antibody-drug conjugate (ADC) (161)
Approvals (16352)
Artificial intelligence (304)
Autoimmune disease (28)
Automation (18)
Bankruptcy (362)
Best Places to Work (11715)
BIOSECURE Act (19)
Biosimilars (116)
Biotechnology (195)
Bladder cancer (91)
Brain cancer (33)
Breast cancer (362)
Cancer (2835)
Cardiovascular disease (216)
Career advice (1702)
Career pathing (30)
CAR-T (183)
CDC (30)
Cell therapy (493)
Cervical cancer (22)
Clinical research (67380)
Collaboration (1000)
Company closure (3)
Compensation (640)
Complete response letters (21)
COVID-19 (2728)
CRISPR (56)
C-suite (302)
Cystic fibrosis (111)
Data (2881)
Decentralized trials (2)
Denatured (20)
Depression (54)
Diabetes (342)
Diagnostics (6469)
Digital health (24)
Diversity (8)
Diversity, equity & inclusion (45)
Drug discovery (138)
Drug pricing (121)
Drug shortages (27)
Duchenne muscular dystrophy (124)
Earnings (87599)
Editorial (41)
Employer branding (21)
Employer resources (148)
Events (114346)
Executive appointments (844)
FDA (17948)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (912)
Gene editing (129)
Generative AI (21)
Gene therapy (377)
GLP-1 (786)
Government (4530)
Grass and pollen (5)
Guidances (180)
Healthcare (18947)
Huntington's disease (31)
IgA nephropathy (42)
Immunology and inflammation (150)
Immuno-oncology (8)
Indications (39)
Infectious disease (2889)
Inflammatory bowel disease (150)
Inflation Reduction Act (10)
Influenza (59)
Intellectual property (115)
Interviews (314)
IPO (16638)
IRA (44)
Job creations (3655)
Job search strategy (1442)
Kidney cancer (13)
Labor market (51)
Layoffs (492)
Leadership (19)
Legal (7959)
Liver cancer (80)
Lung cancer (404)
Lymphoma (202)
Machine learning (9)
Management (58)
Manufacturing (369)
MASH (87)
Medical device (13458)
Medtech (13463)
Mergers & acquisitions (19658)
Metabolic disorders (837)
Multiple sclerosis (99)
NASH (18)
Neurodegenerative disease (117)
Neuropsychiatric disorders (32)
Neuroscience (2129)
NextGen: Class of 2025 (6589)
Non-profit (4513)
Now hiring (47)
Obesity (426)
Opinion (227)
Ovarian cancer (99)
Pain (101)
Pancreatic cancer (118)
Parkinson's disease (186)
Partnered (22)
Patents (292)
Patient recruitment (148)
Peanut (51)
People (57957)
Pharmaceutical (64)
Pharmacy benefit managers (20)
Phase I (21061)
Phase II (29643)
Phase III (22088)
Pipeline (1583)
Policy (194)
Postmarket research (2587)
Preclinical (9091)
Press Release (69)
Prostate cancer (138)
Psychedelics (33)
Radiopharmaceuticals (257)
Rare diseases (460)
Real estate (5960)
Recruiting (66)
Regulatory (22719)
Reports (50)
Research institute (2408)
Resumes & cover letters (355)
Rett syndrome (9)
RNA editing (9)
RSV (47)
Schizophrenia (80)
Series A (152)
Series B (100)
Service/supplier (11)
Sickle cell disease (59)
Special edition (18)
Spinal muscular atrophy (154)
Sponsored (32)
Startups (3650)
State (2)
Stomach cancer (16)
Supply chain (73)
Tariffs (56)
The Weekly (35)
Vaccines (794)
Venture capital (51)
Weight loss (261)
Women's health (43)
Worklife (16)
Date
Last 7 days (615)
Last 30 days (2163)
Last 365 days (31445)
2025 (16076)
2024 (35542)
2023 (40394)
2022 (51534)
2021 (56043)
2020 (54428)
2019 (46903)
2018 (35301)
2017 (32484)
2016 (31875)
2015 (37900)
2014 (31660)
2013 (26918)
2012 (29040)
2011 (29663)
2010 (27710)
Location
Africa (733)
Alabama (61)
Alaska (7)
Arizona (245)
Arkansas (13)
Asia (38805)
Australia (6382)
California (7311)
Canada (2292)
China (659)
Colorado (312)
Connecticut (313)
Delaware (190)
Europe (84236)
Florida (1095)
Georgia (244)
Hawaii (1)
Idaho (60)
Illinois (629)
India (26)
Indiana (357)
Iowa (17)
Japan (220)
Kansas (108)
Kentucky (28)
Louisiana (15)
Maine (64)
Maryland (1011)
Massachusetts (5453)
Michigan (244)
Minnesota (447)
Mississippi (3)
Missouri (88)
Montana (28)
Nebraska (25)
Nevada (79)
New Hampshire (66)
New Jersey (2036)
New Mexico (29)
New York (2059)
North Carolina (1073)
North Dakota (10)
Northern California (3208)
Ohio (229)
Oklahoma (16)
Oregon (34)
Pennsylvania (1590)
Puerto Rico (17)
Rhode Island (36)
South America (1115)
South Carolina (33)
South Dakota (1)
Southern California (2710)
Tennessee (124)
Texas (1092)
United States (27151)
Utah (216)
Virginia (181)
Washington D.C. (72)
Washington State (626)
West Virginia (4)
Wisconsin (64)
712,246 Results for "protein metrics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Collaboration
Sanofi, Gilead Deepen Protein Degrader Pipelines in Separate Deals With Kymera
Gilead is betting up to $750 million on Kymera’s anti-CDK2 molecular glue for solid tumors, while Sanofi elected to move forward with another protein degrader from the biotech, designed to target immune-mediated diseases.
June 25, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa “Blue Zone”, Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World’s Longest-Lived Population
June 24, 2025
·
5 min read
Press Releases
Fujirebio Boosts Product Visibility With Bioz, Achieving Industry-Leading Engagement Metrics
May 28, 2025
·
3 min read
Press Releases
Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
June 12, 2025
·
10 min read
Immunology and inflammation
Kymera Soars on Early Protein Degrader Data
The candidate is being positioned as a potential oral competitor to Sanofi and Regeneron’s blockbuster Dupixent in allergy and inflammation indications.
June 3, 2025
·
1 min read
·
David Adam
Press Releases
IonQ and Kipu Quantum Break New Performance Records For Protein Folding And Optimization Problems
June 19, 2025
·
7 min read
Press Releases
Nuclera and Cytiva Collaborate to Accelerate Characterization of Proteins for Drug Development
May 28, 2025
·
2 min read
Press Releases
Quantum-Si Customer to Showcase Protein Barcoding for Nucleic Acid–LNP Therapeutic Development at Festival of Genomics Boston
June 18, 2025
·
5 min read
Funding
SpliceBio Nabs $135 Million Series B To Advance Protein Splicing Medicines
The company’s intein-based technology is initially aimed at Stargardt disease, a type of macular degeneration.
June 11, 2025
·
2 min read
·
Dan Samorodnitsky
Funding
Novo-Backed GlycoEra Raises $130M To Advance Protein Degraders for Precision Immunology
GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific kinase myasthenia gravis and pemphigus.
May 27, 2025
·
2 min read
·
Tristan Manalac
1 of 71,225
Next
